Whit Bernard, Metsera CEO
March 27, 2025 01:51 PM EDT
Startups
Pharma

Ex­clu­sive: Met­sera CEO on what it takes to build an obe­si­ty biotech in 2025

Kyle LaHucik

Senior Reporter

Met­sera, one of the few biotechs to com­plete an IPO this year, is mak­ing its best ef­fort to catch up to the obe­si­ty drug gi­ants …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

TRENDING NOW

Phar­ma's wins and loss­es in Trump's sprawl­ing ex­ec­u­tive or­der on drug prices

Biotech seed rounds sink to low­est lev­el in years as in­dus­try slump drags on

Sanofi to pay $125M up­front for two im­munol­o­gy drugs from lit­tle-known biotech

US drugs re­ly heav­i­ly on in­gre­di­ents made over­seas, new re­port shows

Sarep­ta los­es CMO to RNA edit­ing up­start; An­oth­er wave of per­son­nel moves at Dyne

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times